title: [Primary lymphoma of breast: a clinicopathologic, immunophenotypic and prognostic study of 21 cases].
abstract: OBJECTIVE
  To investigate the clinicopathologic and immunophenotypic features of primary breast lymphoma (PBL) and to discuss the diagnosis of the tumor.
  
  
  METHODS
  Twenty-one cases of PBL with follow up data were clinically reviewed. The histologic diagnosis of the tumor was based on the updated WHO Classification of tumors of hematopoietic and lymphoid tissues (2008). Immunohistochemistry was performed by SP method and antibodies selected were as follows: CD20, CD3epsilon, CD10, Bcl-6, MUM-1, CD5, Bcl-2, CD23, CD10, cyclin D1, CD43 and Ki67.
  
  
  RESULTS
  (1) All 21 patients were female and the median age of patients was 48 years. The right and the left breasts were involved in 11 (52.4%) and 10 patients (47.6%), respectively. According to Ann Arbor staging system, 20 cases were stage I-II (95.2%), and the remaining case was stage IV (4.8%). For the international prognostic index (IPI), 19 cases were score 0-1, and 2 cases were score 2-3. For ECOG score, 19 cases were 0, and the remaining 2 cases were 1. (2) Histologically, all 21 cases (100%) were DLBCL. Immunohistochemically, the frequency of antigen expression was as follows: CD20 (100%), MUM-1 (14/21, 66.7%), bcl-6 (5/21, 23.8%), CD10 (0), bcl-2 (13/21, 61.9%), CD5 (1/21, 4.8%); Ki-67 index: 10 cases (47.6%) were less than 59%, with the expression of seven cases (33.3%) being 60% - 89%, and more than 90% in the remaining four cases (19.1%). The median Ki-67 index was 60%. All the cases were considered non germinal center B-cell-like type of DLBCL. (3) Follow-up data was available in 64% of the cases. One, two and five-year survival rates were 11 cases, 7 cases and 3 cases, respectively.
  
  
  CONCLUSIONS
  All the cases of PBL in the current study were DLBCL, non germinal center B-cell-like type, and a diagnosis of PBL can only be established after excluding breast involvement in systemic lymphoma.
authors.affiliation: Department of Pathology, West-China Hospital of Sichuan University, Chengdu 610041, China.
authors.forename: Xiao-qing
authors.initials: XQ
authors.lastname: Wang
authors.forename: Le-xing
authors.initials: LX
authors.lastname: Zhang
authors.forename: Cheng-feng
authors.initials: CF
authors.lastname: Bi
authors.forename: Tian-you
authors.initials: TY
authors.lastname: Luo
authors.forename: Li
authors.initials: L
authors.lastname: Lin
authors.forename: Min
authors.initials: M
authors.lastname: Min
authors.forename: Yong
authors.initials: Y
authors.lastname: Zhao
authors.forename: Gui-xiang
authors.initials: GX
authors.lastname: He
authors.forename: Jiang
authors.initials: J
authors.lastname: Feng
authors.forename: Wei-ping
authors.initials: WP
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D018951:Antigens, CD20 / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D050835:Interferon Regulatory Factors / Q000378:metabolism; D019394:Ki-67 Antigen / Q000378:metabolism; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology* / Q000601:surgery; D015409:Mastectomy, Radical; D008875:Middle Aged; D009367:Neoplasm Staging; D011241:Prednisone / Q000627:therapeutic use; D051560:Proto-Oncogene Proteins c-bcl-6 / Q000378:metabolism; D012189:Retrospective Studies; D015996:Survival Rate; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult; D000099218:Interferon Regulatory Factor-4
chemical_list: D018951:Antigens, CD20; D003520:Cyclophosphamide; D004317:Doxorubicin; D050835:Interferon Regulatory Factors; D019394:Ki-67 Antigen; D011241:Prednisone; D051560:Proto-Oncogene Proteins c-bcl-6; D014750:Vincristine; D000099218:Interferon Regulatory Factor-4